Roche Acquires Adheron Therapeutics for up to $580M

Oct 12, 2015

Reuters

Roche will acquire Adheron Therapeutics in a deal worth up to $580 million, according to a Reuters article.

Adheron, a California-based biotech, offers technology that disrupts immune cell adhesion through a protein called Cadherin-11. Its lead asset, SDP051, is a humanized monoclonal antibody that has completed Phase 1 of clinical development.

Adheron's shareholders will get $105 million in cash, plus up to $475 million in potential milestones. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments